Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, vehicle-controlled, dose-finding, multi-center, phase 2a trial of FOL-005 topical formulations to investigate hair growth potential and safety in healthy male volunteers with androgenetic alopecia

Trial Profile

A randomized, double-blind, vehicle-controlled, dose-finding, multi-center, phase 2a trial of FOL-005 topical formulations to investigate hair growth potential and safety in healthy male volunteers with androgenetic alopecia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FOL 005 (Primary)
  • Indications Alopecia
  • Focus Therapeutic Use
  • Sponsors Follicum AB
  • Most Recent Events

    • 15 Sep 2021 According to a Follicum AB media release, following the spring results from this phase 2 study of FOL-005 in the treatment of hair loss, the board decided to evaluate the company's business strategy and long-term goals.
    • 03 Jun 2021 According to a Follicum AB media release, It is currently not possible to assess whether the new analysis will result in any reassessment of the conclusions previously drawn on the drug candidates effect on hair loss. Follicum will return as soon as possible with the results of the re-analysis.
    • 03 Jun 2021 According to a Follicum AB media release, the contract research organization (CRO) together with Follicum, has discovered possible inaccuracies in the results analysis of this trial . Follicum has hired an independent reviewer who will now review all study data and assess the extent to which this affects the recently reported results.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top